<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980002</url>
  </required_header>
  <id_info>
    <org_study_id>IHBDH-IIT2018009</org_study_id>
    <nct_id>NCT03980002</nct_id>
  </id_info>
  <brief_title>A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL</brief_title>
  <acronym>BDHCLL001</acronym>
  <official_title>A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter phase 2 study designed with the purpose to evaluate the
      response rate and safety of treatment with FCR/BR alternating with ibrutinib in
      treatment-naive patients with chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CRR</measure>
    <time_frame>3 months after completion of induction therapy</time_frame>
    <description>Rate of complete remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months after completion of induction therapy</time_frame>
    <description>Overall Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>5 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD negative rate</measure>
    <time_frame>3 months after completion of induction therapy</time_frame>
    <description>the rate of undetectable tumor cells in bone marrow and/or peripheral blood by multicolor flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>5 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related side effects</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FCR/BR alternating with ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FCR/BR→ ibrutinib✖️3months→FCR/BR→ ibrutinib✖️3months→FCR/BR→Maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FCR and Ibrutinib</intervention_name>
    <description>Induction treatment:
Patients &lt;65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count &lt;10×10^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.
FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；
Ibrutinib:420mg/d</description>
    <arm_group_label>FCR/BR alternating with ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR and Ibrutinib</intervention_name>
    <description>Induction treatment:
Patients ≥65y and ≤75 y or &lt;65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d</description>
    <arm_group_label>FCR/BR alternating with ibrutinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib and Thalidomide</intervention_name>
    <description>Maintenance treatment:
After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy.</description>
    <arm_group_label>FCR/BR alternating with ibrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women ≥ 18 years and ≤ 75 of age.

          2. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria.

          3. Treatment-naive patients. Those patients received short-term substandard treatment are
             permitted if meet all the items listed below:

               1. Untreated with combined chemotherapy such as CHOP ,COP and so on.

               2. Unteated with chemotherapy regimens including fludarabine and bendamustine.

               3. Unteated with Ibrutinib.

               4. If treated with chlorambucil or cyclophosphamide,should less than 3 weeks.

               5. If treated with interferon, should less than 6 months.

               6. No objective response are achieved (PR or CR).

          4. CLL/SLL requiring treatment as defined by at least one of the following criteria:

               1. Development of, or worsening of, anemia to Hb&lt;100g/L (non-hemolytic) .

               2. Development of, or worsening of, thrombocytopenia to PLT&lt;100,000/L.

               3. Massive (≥ 6 cm below left costal margin), progressive or symptomatic
                  splenomegaly.

               4. Massive nodes (≥ 10 cm in longest diameter), or progressive or symptomatic
                  lymphadenopathy .

               5. Progressive lymphocytosis with an increase of &gt; 50% over a 2-month period or
                  lymphocyte-doubling time of &lt; 6 months. Lymphocyte-doubling time may be obtained
                  by linear regression extrapolation of absolute lymphocyte counts obtained at
                  intervals of 2 weeks over an observation period of 2 to 3 months. In patients
                  with initial blood lymphocyte counts of &lt; 30,000/L, LDT should not be used as a
                  single parameter to define treatment indication. In addition, factors
                  contributing to lymphocytosis or lymphadenopathy other than CLL/SLL (eg,
                  infection, use glucocorticoid) should be excluded. f)Symptomatic or functional
                  extranodal sites involved s (eg. Skin,kidney, lungs and so on).

             g)Constitutional symptoms, defined as any 1 or more of the following disease-related
             symptoms or signs: i. Unintentional weight loss of ≥ 10% within the previous 6 months
             ii.Significant fatigue (ie, inability to work or perform usual activities)

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          6. Expected to survival period for 3 months or more.

        Exclusion Criteria:

          1. History of malignant tumour except CLL in the past 1year(including active central
             nervous system (CNS) involvement with lymphoma).

          2. Transformed to large cell lymphoma manifested by clinical evidence, or progressed to
             prolymphocytic leukemia(PLL).

          3. Have active autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura, and
             require treatment.

          4. Inadequate hepatic and renal function defined as: AST and ALT &gt;4.0 x upper limit of
             normal (ULN), bilirubin &gt;2.0 x upper limit of normal (ULN), Adequate renal function
             defined by serum creatinine &gt;1.5 x upper limit of normal (ULN),unrelated to lymphoma.

          5. Severe or uncontrolled infection.

          6. Central nervous system (CNS) dysfunction with clinical manifestation.

          7. Other serious medical diseases that may affect the study（eg. Uncontrolled diabetes,
             gastric ulcer, other severe cardiopulmonary disease),and final decided by the
             investigator.

          8. Ongoing and uncontrolled bleeding

          9. History of major life-threatening bleeding, especially due to irreversible cause.

         10. Requirement for continuous anticoagulation drugs.

         11. Major surgery within 30 days(excluding lymph node biopsy).

         12. Pregnant or Lactating women, or women of reproductive age refusal to take
             contraceptive measures.

         13. Allergy to any drug used in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zengjun Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zengjun Li</last_name>
    <phone>+86 13642138692</phone>
    <email>lizengjun@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tingyu Wang</last_name>
    <phone>+86 15692201678</phone>
    <email>wangtingyu@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>30020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zengjun Li</last_name>
      <phone>+86 13642138692</phone>
      <email>lizengjun@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tingyu Wang</last_name>
      <phone>+86 15692201678</phone>
      <email>wangtingyu@ihcams.ac.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zengjun Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tingyu Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>TingyuWang</investigator_full_name>
    <investigator_title>Attending doctor</investigator_title>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Therapeutics</keyword>
  <keyword>ibrutinib</keyword>
  <keyword>fludarabine</keyword>
  <keyword>rituximab</keyword>
  <keyword>bendamustine</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

